Skip to main content

Table 1 Pathological and clinical characteristics

From: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

Variable

All triple negatives; n = 97 (%)

Triple negatives with sufficient FU; n = 71 (%)

Age (years)

  

<41

24 (25)

18 (25)

41–50

33 (34)

30 (42)

>50

40 (41)

23 (32)

Tumor size (cm)

  

≤2.0

34 (35)

23 (32)

>2.0

63 (65)

48 (68)

Number of tumor positive lymph nodes

  

0

54 (56)

35 (49)

1–3

29 (30)

26 (37)

>3

14 (14)

10 (14)

Tumor subtype

  

Adenoid cystic

4 (4)

NA

Apocrine

7 (7)

7 (10)

Ducto-lobular

1 (1)

NA

IDC (nos)

81 (83)

63 (89)

ILC

1 (1)

1 (1)

Metaplastic

3 (3)

NA

Tumor shape

  

Multi-nodular

4 (4)

4 (6)

Stellate

17 (18)

12 (17)

Sharply demarcated/lobulated

76 (78)

55 (76)

Histological grade

  

1

2 (2)

2 (3)

2

8 (8)

4 (6)

3

83 (86)

65 (92)

Adenoid cystic carcinoma not graded

4 (4)

NA

DCIS component around tumor

  

None

79 (81)

56 (79)

Minimal

10 (10)

8 (11)

Moderate

8 (8)

7 (10)

Extensive

NA

NA

DCIS differentiation grade

  

Well

1 (6)

1 (7)

Moderate

NA

NA

Poor

17 (94)

14 (93)

LCIS component

  

None

93 (96)

67 (94)

Present

4 (4)

4 (6)

Vascular invasion

  

None

84 (87)

59 (83)

Present

13 (13)

12 (17)

Lymphocytic infiltrate

  

None

8 (8)

4 (6)

Minimal

40 (41)

34 (48)

Moderate

33 (34)

25 (35)

Extensive

12 (12)

8 (11)

Adenoid cystic carcinoma not graded

4 (4)

NA

Central fibrotic zone

  

None

44 (45)

31 (44)

Present

49 (51)

40 (56)

Adenoid cystic carcinoma not graded

4 (4)

NA

KRT5/6

  

Negative (0% staining)

21 (22)

16 (23)

Positive (> 0% staining)

74 (76)

53 (75)

Unknown

2 (2)

2 (3)

p53

  

Negative (< 50% staining)

47 (49)

33 (47)

Positive (> 49% staining)

48 (50)

36 (51)

Unknown

2 (2)

2 (3)

EGFR

  

Negative (0% staining)

69 (71)

58 (82)

Positive (> 0% staining)

26 (27)

11 (16)

Unknown

2 (2)

2 (3)

KIT

  

Negative (0% staining)

58 (60)

39 (55)

Positive (> 0% staining)

37 (38)

30 (42)

Unknown

2 (2)

2 (3)

Treatment of primary tumor

  

Breast-conservation

61 (63)

45 (63)

Mastectomy

36 (37)

26 (37)

Adjuvant radiotherapy

  

Yes

85 (88)

65 (92)

No

12 (12)

6 (8)

Adjuvant systemic therapy

  

Chemotherapy

47 (48)

37 (52)

Endocrine therapy

13 (13)

11 (15)

Chemotherapy and endocrine therapy

4 (4)

4 (6)

None

33 (34)

19 (27)

Metastasis as first event

  

Yes

NA

17 (24)

No

NA

54 (76)

  1. DCIS, ductal carcinoma in situ; EGFR, epidermal growth factor receptor; FU, follow-up; IDC (nos), infiltrating ductal carcinoma (not otherwise specified); ILC, infiltrating lobular carcinoma; LCIS, lobular carcinoma in situ; NA, not applicable.